Robbins LLP Encourages WGS Stockholders to Join Class Action Against GeneDx Holdings Corp.
Robbins LLP Encourages WGS Stockholders to Take Action
In a significant development for investors, Robbins LLP is actively reaching out to stockholders of GeneDx Holdings Corp. who have incurred losses. The firm has filed a class action on behalf of all individuals who purchased or acquired the company’s common stock between April 16, 2025, and May 4, 2026. GeneDx, a prominent genomics company specializing in genetic testing for pediatric and rare diseases, faces scrutiny regarding its recent acquisition practices.
Background of the Class Action
The class period outlined in the class action spans from April 16, 2025, to May 4, 2026. At the heart of the allegations is the claim that GeneDx misled investors regarding the benefits of its acquisition of Fabric Genomics. In April 2025, GeneDx announced its plan to acquire Fabric, an AI-driven genomic interpretation firm, in a deal valued at up to $51 million. The expectation set by GeneDx was that this acquisition would significantly enhance its market potential and create new revenue streams through innovative business models.
However, following the completion of this acquisition, GeneDx maintained that its collaboration with Fabric would generate recurring revenues through an interpretation-as-a-service model. Investors were led to believe that this partnership would bolster the company’s financial standing and operational efficiencies. Unfortunately, these representations might have been overly optimistic, as claimed in the lawsuit.
Key Allegations
According to the filed complaint, the statements made by GeneDx during the class period included assertions that created a false impression of the acquisition's actual impact on the company's performance. The plaintiff alleges that GeneDx’s executives were either aware of or recklessly ignored significant issues related to Fabric's viability, which ultimately hindered GeneDx’s business performance.
On May 4, 2026, GeneDx reported results for the first quarter of 2026, revealing that it had missed revenue estimates for its exome and genome product lines. This revelation included a significant downward adjustment of its full-year revenue forecast, dropping to $475-$490 million from a prior estimate of $540-$550 million. Furthermore, GeneDx disclosed a $31.2 million impairment loss linked to Fabric's acquisition. As a direct consequence, the company’s stock price plummeted by 49.2%, translating to a loss of $33.42 per share.
What Shareholders Need to Know
The urgent question arises: what steps should shareholders take now? Investors who feel affected by these developments may be eligible to participate in the class action against GeneDx Holdings Corp. Those interested in serving as lead plaintiffs must file their papers with the court by August 3, 2026. A lead plaintiff plays a critical role as a representative of the class, guiding the litigation process. However, it is important to note that there is no obligation to participate in the case. Investors opting out will remain classified as absent class members.
All representation involved in this class action is based on a contingency fee agreement, meaning that shareholders will not have to pay any legal fees or expenses unless there is a successful recovery from the lawsuit.
About Robbins LLP
Robbins LLP has earned a strong reputation in shareholder rights litigation, assisting investors in recovering their losses and enforcing better governance practices within companies. Since its founding in 2002, the firm has remained committed to holding corporate executives accountable for their actions that may harm shareholders.
To stay informed about potential settlements in class actions or to receive alerts regarding corporate misconduct, interested individuals can sign up for Stock Watch services provided by Robbins LLP.
The ongoing situation with GeneDx serves as a reminder for investors to remain vigilant and informed about their investments, particularly in industries as dynamic as genomics. If you have further questions about your eligibility in this case, or if you require additional information, don't hesitate to reach out to Robbins LLP directly via form submission, email, or telephone.
- ---
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.